Skip to main content


for people ages 18–75 (full criteria)
at San Francisco, California and other locations
study started
estimated completion:



The primary purpose is to assess the benefits and risks of changing from Cyclosporine or Tacrolimus to Belatacept between 6-60 months after kidney transplant.

Official Title

Evaluation of the Benefits and Risks in Maintenance Renal Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based Immunosuppression


Kidney Transplantation Tacrolimus Cyclosporins Cyclosporine Abatacept


For people ages 18–75

For more information regarding BMS clinical trial participation, please visit

Inclusion Criteria:

  • Men and women, ages 18-75 inclusive
  • Adult recipients of a renal allograft from a living donor or a deceased donor between 6-60 months prior to enrollment
  • Receiving a stable (≥1 month) regimen of Calcineurin inhibitor (CNI) [Cyclosporine A(CsA) or Tacrolimus (TAC)] with Mycophenolate mofetil (MMF) or Enteric Coated Mycophenolate Sodium (EC-MPS)/Mycophenolic acid (MPA), and corticosteroids
  • Stable renal function for 12 weeks prior to enrollment without new onset proteinuria
  • Calculated glomerular filtration rate (cGFR) ≥30 and ≤75 mL/min/1.73 m2 [Modification of Diet in Renal Disease study (MDRD) 4-formula]

Exclusion Criteria:

  • Recipients with Epstein-Barr virus (EBV) serostatus negative or unknown
  • History of acute rejection (AR) within 3 months prior to enrollment
  • History of antibody mediated rejection
  • Positive T-cell lymphocytotoxic cross match
  • Proteinuria >1 g/day or >0.5 g/day if diabetic


  • UCSF Medical Center
    San Francisco, California, 94143, United States
  • California Pacific Medical Center, Depart of Transplantation (PI Address)
    San Francisco, California, 94115, United States
  • University of California, San Francisco (UCSF)-Kidney Transplant Service
    Sacramento, California, 95817, United States
  • UCLA Kidney Transplant Research Office
    Los Angeles, California, 90095-6984, United States
  • Cedars-Sinai Medical Center-Kidney and Pancreas Transplant Center
    Los Angeles, California, 90048, United States
  • Transplant Research Institute (PI Address)
    Los Angeles, California, 90057, United States
  • Keck Medical Center of USC (PI Address)
    Los Angeles, California, 90033, United States
  • Loma Linda University Medical Center (LLUMC) - Children's Hospital - Transplantation Institute
    Loma Linda, California, 92354, United States


in progress, not accepting new patients
Start Date
Completion Date
Bristol-Myers Squibb
BMS Clinical Trial Information
FDA Safety Alerts and Recalls
BMS Clinical Trial Patient Recruiting
Investigator Inquiry Form
Phase 3
Lead Scientist
Flavio Vincenti
Study Type
Last Updated
February 26, 2018